Healthcare News

HAIFA, Israel, Dec. 4, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that it has entered...

Uppsala, 2014-12-04 08:15 CET (GLOBE NEWSWIRE) --   ANDRA KVARTALET 1 augusti – 31 oktober 2014 Koncernens nettoomsättning uppgick till 558 tkr (24) [1] Rörelseresultatet var -24 145...

Uppsala, Sweden, 2014-12-04 08:15 CET (GLOBE NEWSWIRE) --   SECOND QUARTER    August 1 – October 31, 2014 Consolidated Net sales amounted to TSEK 558 (24)[1] Operating...

First human trial investigating MVA-BN® Filo as an Ebola vaccine MVA-BN Filo is being investigated as a booster in an ongoing Phase study 1 of the cAd3-EBO Z vaccine being developed by...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} First human trial investigating MVA-BN® Filo...

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Forsøget er det første i mennesker, hvor...

ATLANTA, USA, 4 december 2014 – För att erbjuda högteknologisk cancervård i South Dakota, Minnesota, och närliggande stater har Avera Health och Elekta (EKTA-B.ST) ingått ett samarbete kring...

ATLANTA, December 4, 2014 – To provide high-quality, evidence-based cancer care throughout South Dakota, Minnesota and other surrounding states, Avera Health and Elekta (EKTA-B.ST) announce a...

Company Announcement First study of daratumumab outside of multiple myeloma Study expected to begin enrolling in 2015 Copenhagen, Denmark; December 4, 2014 – Genmab A/S (OMX: GEN)...

Selskabsmeddelelse Første studie med daratumumab uden for myelomatose Rekruttering til studiet ventes indledt i 2015 København, Danmark; 4. december 2014 – Genmab A/S (OMX: GEN) har i...